Biomarker of renal dysfunction

Patent metadata

Field	Value
Publication number	US-10371706-B2
Application number	US-201314407603-A
Country	US
Kind code	B2
Filing date	Jun 13, 2013
Priority date	Jun 14, 2012
Publication date	Aug 6, 2019
Grant date	Aug 6, 2019

Abstract

The present invention relates to a method for determining predisposition of a subject to developing renal dysfunction induced by physical trauma, hypotension, sepsis and/or septic shock syndrome, wherein the method comprises the steps of:—a. determining the level of an anti-inflammatory cytokine present in a sample taken from the subject prior to physical trauma, prior to a hypotensive event, prior to sepsis, and/or prior to septic shock syndrome; b. determining if the subject is predisposed to developing renal dysfunction following physical trauma, hypotension, sepsis and/or septic shock syndrome on the basis of the level of an anti-inflammatory cytokine determined in step a).

First claim

The invention claimed is:

1. A method of treating a subject at increased risk of renal dysfunction induced by a planned physical trauma, wherein the method comprises the step of:
a) obtaining a urine sample from a subject prior to the planned physical trauma, wherein the planned physical trauma is elective surgery;
b) detecting the anti-inflammatory cytokine present in the urine sample obtained in step a), wherein the anti-inflammatory cytokine is selected from the group consisting of IL-1ra, TNFsr1 and TNFsr2 and any combination thereof;
c) detecting the anti-inflammatory cytokine in a pre-event normal control, wherein the pre-event normal control is a normal level of anti-inflammatory cytokine presented by a control group or a predetermined normal cytokine level;
d) calculating the level of anti-inflammatory cytokine detected in step b) relative to the level of anti-inflammatory cytokine detected in step c);
e) determining that the subject has a greater than normal chance of developing renal dysfunction induced by planned physical trauma when the level of anti-inflammatory cytokine determined in step b) is lower than the level of anti-inflammatory cytokine detected in step c); and
f) applying therapeutic measures to treat or obviate renal dysfunction to the subject, wherein the therapeutic measures are selected from maintaining a supra-normal blood pressure; ensuring adequate tissue oxygen delivery; administration of steroids; renal replacement therapy; dialysis; or any combination thereof.

Assignees

• Univ Belfast
• Belfast Health And Social Care Trust

Inventors

• Mcbride William Thomas
• Armstrong Marilyn

Classifications

• G01N2800/32

  Cardiovascular disorders · CPC title

• G01N33/6869 Primary

  Interleukin · CPC title

• G01N33/6863 Primary

  Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors · CPC title

• G01N2333/7151

  for tumor necrosis factor [TNF]; for lymphotoxin [LT] · CPC title

• G01N2333/7155

  for interleukins [IL] · CPC title